Even targeting multiple pathways like sorafenib, a multikinase inhibitor of Raf, VEGFR, and platelet-derived growth factor receptor-β, only increased the median overall survival by two months in advanced HCC [50]. The gene discussed is KDR; the disease is hepatocellular carcinoma.